Karilyn Larkin, MD

Karilyn Larkin, MD, traces her equity focus to her medically underserved hometown, urging new diagnostics, trial design, and honest patient talks to close AML gaps.

Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.